Regulating viral replication using RNA aptazymes

Regulating viral replication using RNA aptazymes

The biggest problem in cancer therapeutics is selectivity. Using oncolytic viral therapies, high selectivity can be achieved using the combination of selective infection and selective replication. Here, we want to address selective replication. For DNA viruses, this can be accomplished with promoters to control transcription and genome replication.  However, for RNA viruses, this does not work. A potential solution to control replication for RNA viruses is the use of aptazymes. Aptazymes are self-cleaving units composed of a riboswitch and an aptamer….

Rational Design of Oncolytic Viruses

Rational Design of Oncolytic Viruses

In this post we give an overview of the history of using viruses as potential treatment for cancer. We also outline the challenges a great viral therapy needs to overcome. Last, we review our approach to rationally design and engineer safe and effective oncolytic viruses. History and current state Since the middle of the last century there has been anecdotal evidence that virus infections can help in curing or slowing down cancer. Unfortunately these infections happened randomly and the results…

Our platform

Our platform

In this post, I would like to introduce the Humane Genomics Artificial Virus Platform. Why develop an artificial virus platform? For decades, a lot of research has been conducted to see if natural viruses can be used as cancer therapeutics, with limited success. Over the last 10 years, the technology to engineer, to build viruses specifically as cancer therapeutics has matured. However, most technology approaches to make these viruses are complicated, error prone, time consuming and expensive. To address these…